CalciMedica reports Q1 net income $5.0M; FDA feedback on Auxora pivotal program expected Q2 2026

CalciMedica, Inc.

2026-Q1 EPS reported $0.30

Net income $5.0M ($0.31 basic) vs net loss $5.0M a year ago; cash $8.2M as of March 31, 2026.
R&D expenses $3.5M, G&A $2.1M; other income $10.6M from fair value adjustments on warrants and note.
FDA feedback on pivotal program design for Auxora in acute pancreatitis expected in Q2 2026.
IND submission for oral CRAC inhibitor CM5480 in pulmonary hypertension anticipated in 2027.
Phase 2b CARPO results published: Auxora showed 100% reduction in new-onset severe respiratory failure (p<0.05).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

CalciMedica, Inc. reported first quarter ended March 31, 2026 results: net income Net income was $5.0 million, EPS $0.31 per basic share and $0.30 per diluted share.

Period: first quarter ended March 31, 2026
Net income: Net income was $5.0 million
EPS: $0.31 per basic share and $0.30 per diluted share
Result: reported results

Exact text from the filing

Net income was $5.0 million, or $0.31 per basic share and $0.30 per diluted share, for the three months ended March 31, 2026, compared to a net loss of $5.0 million, or $0.36 per basic

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-218134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.